Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

Connie Batlevi,Paul A. Hamlin,Matthew J. Matasar,Steven M. Horwitz,John F. Gerecitano,Craig H. Moskowitz,David J. Straus,Andrew D. Zelenetz,Pamela Drullinsky,Amanda R. Copeland,Salma Ahsanuddin,Devin Callan,Benjamin Freidin,Robert Porzio,Thu Oanh Dang,Ai Ni,Jürgen Rademaker,Heiko Schöder,Ahmet Dogan,Anas Younes

Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

2017

7544Background: In vitro studies of BTK and PI3K inhibitors demonstrate synergy in non-Hodgkin lymphoma (NHL). We embarked on a phase I/Ib investigator-initiated clinical trial evaluating the combi...

Keywords:

Follicular lymphoma
Buparlisib
Refractory Diffuse Large B-Cell Lymphoma
Pathology
Cancer research
Mantle cell lymphoma
Medicine
Ibrutinib
Lymphoma
dose escalation
Diffuse large B-cell lymphoma
Bruton's tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations